Maraviroc placebo

DRUG2 trials

Sponsors

Pfizer, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Arthritis, RheumatoidHIV Infection

Phase 2

Maraviroc in Rheumatoid Arthritis

TerminatedNCT00427934

PfizerArthritis, Rheumatoid

Start: 2007-02-28End: 2008-10-31Updated: 2014-11-05

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

CompletedNCT01505114

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2012-06-30End: 2015-11-30Updated: 2021-11-05

Related Papers

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

PLoS ONE2018-12-264 citations

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.

2017-08-2228 citations

PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305)

The Journal of Infectious Diseases2016-10-3147 citations

A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)

PLoS ONE2015-05-0557 citations

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.

2012-01-1756 citations